Australia's Ventracor Appoints US-based Medical Device Veteran as COO to Lead Strategic Marketing, Sales and Distribution in USA

Australia's Ventracor Appoints US-based Medical Device Veteran as
COO to Lead Strategic Marketing, Sales and Distribution in USA and Europe 


SYDNEY, Feb. 18  /PRNewswire-FirstCall/ -- International medical technology
company, Ventracor Limited (OTC:VTCRY)(ASX:VCR), today announced the immediate
appointment of Mr. Peter Crosby as Chief Operating Officer to lead the
company's strategic marketing, sales and distribution in Europe and the USA.

Mr. Crosby will initially focus on marketing and sales of the VentrAssist(TM)
left ventricular assist system (LVAS), as well as clinical trials and
regulatory approvals. He brings to Ventracor more than 20 years experience in
the global commercialisation of cardiac medical devices and specialist skills
in product development, marketing, strategic planning and business development.

"We are pleased Ventracor has attracted such a widely experienced and well
respected medical device executive to join our team and lead our international
efforts to rapidly commercialise the VentrAssist(TM), " Ventracor's Chief
Executive Officer and Managing Director, Colin Sutton, PhD, said.

Mr. Crosby has been the CEO of four medical device companies in three countries
and was most recently President and CEO of Ischemia Technologies, a
Denver-based company that developed a new and proprietary diagnostic test for
cardiac ischemia.

Mr. Crosby is a member of the Board of Directors of Cardiac Science Inc
(NASDAQ:DFIB), a developer and manufacturer of automatic external
defibrillators (AED). Mr. Crosby also serves as Chairman of the Board of
CardioComm Solutions, Inc, a Canadian developer of software products and
Internet solutions for ECG management.

He holds a Bachelor of Science in Electrical Engineering and a Master of
Engineering Science from the University of Melbourne, Australia. Mr. Crosby
will be based in the US.

About Ventracor

Ventracor (OTC:VTCRY)(ASX:VCR) is an international medical technology company
that has developed a life-saving heart pump, the VentrAssist(TM) left
ventricular assist system (LVAS), for patients in cardiac failure. The company
is focused on commercializing the VentrAssist(TM) and bringing it to global
markets in record time. Ventracor is confident of obtaining a significant share
of the massive LVAS market, which independent analysts expect to be valued at
between $US7.5 billion and $US12 billion per year.

The VentrAssist(TM) LVAS

The VentrAssist(TM) LVAS provides left heart support and is designed as a
permanent alternative to a heart transplant. The titanium alloy pump is
implanted below the diaphragm and is connected to the circulatory system using
standard fabric tubes known as vascular grafts. The device itself is 2.5 inches
(60 mm) in diameter and weighs just 10oz (298 grams). 

DATASOURCE: Ventracor Limited



CONTACT:  Ventracor Limited, [phone], 



Web site:  http://www.ventracor.com/ 

Copyright